Myeloma
If it’s your first time on this website, please read the disclaimer section.
Oct 05 – Oct 12, 2026
Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review explores how metabolic insights can boost CAR T cell efficacy in cancer, particularly for solid tumours. It examines the impact of CAR design, manufacturing platforms, and host metabolism on T cell fitness and antitumour activity. The abstract highlights that co-stimulatory domains induce distinct metabolic profiles and that manufacturing protocols lack standardization. It proposes leveraging diet-based interventions as a clinically accessible strategy to enhance CAR T cell therapy, aiming for more durable responses in cancer patients.
10.1038/s41568-026-00984-2
Sep 28 – Oct 05, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This ASCO living guideline provides updated, evidence-based recommendations for the systemic treatment of patients with multiple myeloma. The methodology involves a systematic review of clinical trials to evaluate the efficacy of induction, consolidation, and maintenance therapies. Key findings emphasize the use of quadruplet regimens and proteasome inhibitors, which have significantly improved progression-free survival and minimal residual disease (MRD) negativity rates in recent trials. These recommendations are directly relevant to oncology practice, offering a definitive framework for managing this hematologic malignancy through various stages of disease progression.
10.1200/JCO-26-02399
Sep 21 – Sep 28, 2026
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
The EXCALIBER-RRMM phase 3 trial compared iberdomide, daratumumab, and dexamethasone (IDd) with daratumumab, bortezomib, and dexamethasone (DVd) in 420 patients with relapsed or refractory multiple myeloma. IDd significantly improved minimal residual disease (MRD)-negative complete response, achieved in 41% (85/207) of patients versus 21% (44/213) with DVd (proportion difference 20.1%, p<0.0001). This demonstrates a superior treatment option for a specific cancer, directly addressing the clinician’s interest in cancer research. IDd represents an efficacious new regimen for relapsed or refractory multiple myeloma, potentially improving outcomes for these cancer patients.
10.1016/S1470-2045(26)00450-X
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase III CEPHEUS subgroup analysis evaluated the efficacy and safety of adding daratumumab to bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd alone in 289 transplant-ineligible patients with newly diagnosed multiple myeloma. At 58.7 months follow-up, DVRd significantly increased MRD negativity rates to 60.4% compared to 39.3% for VRd (p=.0004) and reduced the risk of disease progression or death by 49% (HR 0.51). The quadruplet regimen also demonstrated superior sustained MRD negativity for ≥24 months (40.3% vs 22.8%), indicating deeper and more durable responses in this older or comorbid population. These findings reinforce DVRd as a potent standard of care for transplant-ineligible patients, offering substantial progression-free survival benefits with a manageable safety profile.
10.1200/JCO-26-00401
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This Phase 1 study investigated the safety and efficacy of anito-cel, a novel BCMA CAR T-cell therapy, in 38 patients with relapsed or refractory multiple myeloma. At a median follow-up of 38.1 months, the therapy achieved a 100% overall response rate, with 79% complete responses. Notably, grade 3 or higher cytokine release syndrome and ICANS were rare (0% and 3% respectively at the recommended phase 2 dose). With a 24-month progression-free survival of 57% and 36-month overall survival of 65%, anito-cel offers a promising, durable treatment option for this challenging cancer.
10.1056/NEJMoa2603527
Sep 07 – Sep 14, 2026
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This review traces the 30-year evolution of immunomodulatory drugs (IMiDs) in multiple myeloma, linking clinical advances to cereblon E3 ligase modulation and neosubstrate degradation. It covers thalidomide repurposing, lenalidomide’s Rd backbone and maintenance, and pomalidomide’s efficacy after lenalidomide failure. Next-generation cereblon E3 ligase modulators (CELMoDs) iberdomide and mezigdomide are highlighted for overcoming IMiD-refractory, triple-class-exposed disease, with early clinical data and rational combinations. The review proposes a pragmatic framework for positioning CELMoDs in an immunotherapy-rich era, emphasizing scalable oral agents for relapsed/refractory myeloma.
10.1200/JCO-26-00545
Treatment Decisions in Multiple Myeloma.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This abstract provides a practical framework for navigating treatment decisions in multiple myeloma, a hematological cancer. It outlines how cytogenetic and genomic risk stratification, functional fitness, and measurable residual disease status individualize therapy in newly diagnosed disease, where quadruplet induction is standard and autologous transplantation is reevaluated. For relapse, it addresses sequencing of B-cell maturation antigen-directed CAR T cells, bispecific antibodies, and antibody-drug conjugates, emphasizing T-cell fitness and multiantigen targeting. The primary implication is to guide clinicians in personalizing therapy across the disease spectrum and encourage clinical trial enrollment for continued progress in cancer treatment.
10.1056/NEJMra2605253
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 2 externally controlled trial evaluated intensified induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in 107 patients with high-risk multiple myeloma, compared to 120 genetically matched controls from the Myeloma XI trial. At a median follow-up of 71.1 months, progression-free survival was not reached versus 24.4 months (HR 0.32, 95% CI 0.22-0.45), and overall survival was not reached versus 57.4 months (HR 0.43, 95% CI 0.28-0.65). The survival benefit was consistent across molecular subgroups except for patients with three or more high-risk cytogenetic abnormalities. This study supports the use of risk-stratified, intensified therapy with molecular diagnostics to improve long-term outcomes in high-risk multiple myeloma, a form of blood cancer.
10.1016/S1470-2045(26)00286-X
Aug 10 – Aug 17, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 trial evaluated cevostamab, a first-in-class FcRH5×CD3 bispecific antibody, in 324 patients with heavily pretreated relapsed or refractory multiple myeloma. At the recommended phase 2 dose of 160 mg, the objective response rate was 44.3% overall and 60.6% in BCMA-naive patients, with a median duration of response reaching 19.7 months in the latter group. Safety analysis showed manageable toxicity, with grade 3/4 adverse events in 59.6% of patients and primarily low-grade cytokine release syndrome using step-up dosing. These findings demonstrate that cevostamab provides a promising, fixed-duration immunotherapy option for late-line myeloma, particularly for those who have not yet received BCMA-targeted therapies.
10.1038/s41591-026-04522-3
Jul 27 – Aug 03, 2026
High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This review addresses controversies in managing high-risk smoldering multiple myeloma (SMM), a precursor to multiple myeloma (MM), by evaluating early treatment versus observation. Randomized trials confirm early treatment delays MM progression, with daratumumab showing significant progression-free survival (HR 0.49, p < .001) and a trend towards improved overall survival (HR 0.52) in high-risk SMM. This challenges the traditional watch-and-wait approach, validating early intervention for selected patients at high cancer risk. Clinically, SMM management should be risk-adapted, considering early treatment for high-risk individuals while acknowledging uncertainties about overall survival benefit and potential overtreatment.
10.1200/JCO-26-00236
Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This review examines the epidemiology, pathophysiology, and evolving therapeutic landscape for systemic light chain (AL) and transthyretin (ATTR) amyloidosis. It highlights the 2021 approval of daratumumab-based quadruplet therapy for AL amyloidosis and the emergence of six novel ATTR therapies since 2018. For oncology-focused clinicians, the study details highly effective immunotherapies like bispecific T-cell engagers currently showing unprecedented efficacy in relapsed AL amyloidosis clinical trials. The findings emphasize the necessity of early suspicion and rapid protein typing to initiate targeted therapies that have transformed these once-fatal conditions into manageable chronic diseases.
10.1016/S0140-6736(26)00302-8
De-escalation trials in multiple myeloma: past, present and future.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review synthesizes emerging evidence on de-escalation strategies for multiple myeloma (MM), aiming to maintain disease control while reducing treatment-related toxicity. The methodology involves analyzing various approaches, including dose modifications, MRD-adapted strategies, omission of autologous stem cell transplantation, and fixed-duration immunotherapy regimens. While specific numerical outcomes from individual trials are not detailed in the abstract, it highlights the transition toward personalized treatment intensity in oncology. These findings are highly relevant for clinicians seeking to balance efficacy with patient quality of life through evidence-based treatment reduction.
10.1038/s41571-026-01186-3